US Digital PCR (dPCR) and Real-Time PCR (qPCR) Market Size, Share & Trends Analysis Report, by Technology (Quantitative PCR and Digital PCR), by Product (Reagents and Consumables, Instruments, and Software), by Application (Research Application, Clinical Application, and Forensic Application) and Forecast, 2019-2025.
The US digital PCR (dPCR) and real-time PCR (qPCR) market is expected to grow at a CAGR of 8.1% during the forecast period. The US is anticipated to hold considerable market share in the global dPCR and qPCR market. The major aspects that contribute to its high market share include the fact that the country emphasizes more towards increasing the treatment efficiency of diseases such as cancer, generating forensic DNA profiles from samples of DNA and processing DNA for sequencing. According to the Research America organization, the US had spent almost $158.7 billion in the R&D of medical and healthcare sector in 2015.
There has been an increase in the US healthcare R&D investment since 2013 till 2015. In 2015, the federal agencies had invested almost a total of $35.9 billion in R&D, with the National Institutes of Health (NIH) that comprises $29.6 billion of share. In March 2019, Promega Corp. announced to award a grant of $10,000 to the labs that are working with real-time PCR reagents. According to the Personalized Medicine Coalition, biopharmaceutical researchers predict a 69% increase in the number of personalized medicines in the development over the next five years. The significant government sending for R&D in healthcare is promoting the R&D of such advanced technology across the country thereby promoting the growth of the dPCR and qPCR market during the forecast period.
The market growth in the country is also attributed to the presence of large players, such as Abbott Laboratories, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., and many others in the country. These key companies are actively adopting various strategies such as new product launches and approvals, merger and acquisition, partnerships and collaborations, and many others in order to thrive in a competitive environment. For instance, in July 2017, Agilent Technologies Inc. expanded its product portfolio and introduced a real-time PCR system for clinical diagnostics. The company expanded the instruments portfolio for the molecular diagnostics segment with the invention of the AriaDx Real-Time PCR System, for in-vitro diagnostic use. Thus, the introduction of such products enhanced the company's growth and revenue generation.
Research Methodology
The market study of the US dPCR and qPCR market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.
Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings authenticity in the reports.
Secondary Sources Include:
Market Segmentation:
The Report covers:
The US digital PCR (dPCR) and real-time PCR (qPCR) market is expected to grow at a CAGR of 8.1% during the forecast period. The US is anticipated to hold considerable market share in the global dPCR and qPCR market. The major aspects that contribute to its high market share include the fact that the country emphasizes more towards increasing the treatment efficiency of diseases such as cancer, generating forensic DNA profiles from samples of DNA and processing DNA for sequencing. According to the Research America organization, the US had spent almost $158.7 billion in the R&D of medical and healthcare sector in 2015.
There has been an increase in the US healthcare R&D investment since 2013 till 2015. In 2015, the federal agencies had invested almost a total of $35.9 billion in R&D, with the National Institutes of Health (NIH) that comprises $29.6 billion of share. In March 2019, Promega Corp. announced to award a grant of $10,000 to the labs that are working with real-time PCR reagents. According to the Personalized Medicine Coalition, biopharmaceutical researchers predict a 69% increase in the number of personalized medicines in the development over the next five years. The significant government sending for R&D in healthcare is promoting the R&D of such advanced technology across the country thereby promoting the growth of the dPCR and qPCR market during the forecast period.
The market growth in the country is also attributed to the presence of large players, such as Abbott Laboratories, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., and many others in the country. These key companies are actively adopting various strategies such as new product launches and approvals, merger and acquisition, partnerships and collaborations, and many others in order to thrive in a competitive environment. For instance, in July 2017, Agilent Technologies Inc. expanded its product portfolio and introduced a real-time PCR system for clinical diagnostics. The company expanded the instruments portfolio for the molecular diagnostics segment with the invention of the AriaDx Real-Time PCR System, for in-vitro diagnostic use. Thus, the introduction of such products enhanced the company's growth and revenue generation.
Research Methodology
The market study of the US dPCR and qPCR market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.
Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings authenticity in the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market
- Whitepapers, research-papers, and news blogs
- Company websites and their product catalog
Market Segmentation:
- US dPCR and qPCR Market Research and Analysis, by Technology
- US dPCR and qPCR Market Research and Analysis, by Product
- US dPCR and qPCR Market Research and Analysis, by Application
The Report covers:
- Comprehensive research methodology of the US dPCR and qPCR market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the US dPCR and qPCR market.
- Insights about market determinants which are stimulating the US dPCR and qPCR market.
- Detailed and extensive market segments with regional distribution of forecast revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Company Profiles
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbott Laboratories, Inc.
- Agilent Technologies, Inc.
- Avance Biosciences
- Becton, Dickinson and Co.
- Biodesix, Inc.
- Bio-Rad Laboratories, Inc.
- Danaher Corp.
- Fluidigm Corp.
- Promega Corp.
- Quantabio
- Thermo Fisher Scientific Inc.
